Drug prices PhRMA earned a major win against legislation that would have stopped drugmakers from denying generic-drug companies the ability to study their products to bring low-cost competition to market. (Photo: Shutterstock)

The drug industry set several quarterly records for lobbying spending in the first three months gof 2018 as it faced pressure from President Donald Trump's administration and lawmakers on drug pricing, generic medicines and trade.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.